GU Cancers Symposium 2013 - High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study, by Abdenour Nabid, et al. - Session Highlights

ORLANDO, FL, USA ( - For patients with high-risk prostate cancer, radiotherapy (RT) and long term androgen blockade (AB) is standard treatment but the optimal duration of treatment has not yet been determined.

[yee_row column-size="md-column" boxed_layout="yee-container-fluid" padding_layout="" style_detail="" theme_options="flattern" border_color="" border="none" background_image_options="none" background_image="" background_color_options="none" background_color="" responsive_column_reset="no" vacolumns="top" ex_class="" id="" visiable="1"][yee_column width="1/1" ors="" column-size="md-column" xs-column="0" xs-hidden="" sm-column="0" sm-hidden="" md-column="0" md-hidden="" lg-column="0" lg-hidden="" hidden-print="visiable" background_image="" background_color="" ex_class="" visiable="1"][yee_text_block css_animation="no" ex_class="" style_detail="" yee-widget-theme="default" border_color="" border="none" visiable="1"]{textblock_content}


nabid thumbnailThe purpose of this randomized study was to compare results between 36 vs.18 months of AB in high-risk prostate cancer patients treated with RT. The included high risk patients had no regional disease and had T3-4, PSA>20 ng/ml or Gleason score >7. They were randomized to either pelvic RT plus 36 months of AB (arm 1, n=310) or pelvic RT plus 18 months of AB (arm 2, n=320). In this case, AB consisted of bicalutamide 50 mg for 1 month, plus goserelin 10.8 mg every three months, for 36 vs. 18 months. Primary end point was overall survival (OS), and the study also looked at disease-specific survival and quality of life outcomes. Median follow up was 77 months, and at that time, the biochemical failure rate in arm 1 was 19% vs. 25% in arm 2, rate of bone metastases in arm 1 was 8.1% vs. 7.8% in arm 2. 22.9% of patients in arm 1 had died vs. 23.8% in arm 2. OS at 5 years was 92.1% for arm 1 vs. 86.8% for arm 2, and at 10 years it was 63.6% for arm 1 vs. 63.2% for arm 2. Disease specific survival at 5 years was 97.6% in arm 1 vs. 96.4% in arm 2, and at 10 years it was 87.2% in arm 1 vs. 87.2% in arm 2. This study shows that AB can be safely reduced from 36 months to 18 months without compromising outcomes. The duration of side effects and treatment cost can be decreased with 18 months of AB compared to 36 months. The quality-of-life data is still under review.


To view the slide presentation,  click here.


Highlights of a presentation by Abdenour Nabid, et al. at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada

View Full 2013 GU Cancers Symposium Coverage